

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN



This announcement is not a prospectus and not an offer of securities for sale in any jurisdiction, including in or into the United States, Canada, Australia or Japan.

Frauenfeld, 17. Juli 2020

Medienmitteilung

Zur Rose Group AG führt erfolgreich Kapitalerhöhung aus genehmigtem Kapital durch und setzt Platzierungspreis bei CHF 287 pro neuer Aktie fest

Zur Rose Group AG (das "Unternehmen" oder "Zur Rose Group") hat erfolgreich die gestern beschlossene Kapitalerhöhung abgeschlossen. Insgesamt wurden 740'823 neue Aktien im Rahmen einer internationalen Privatplatzierung an institutionelle Investoren mit einem Platzierungspreis von CHF 287.00 je neuer Aktie (der "Platzierungspreis") platziert.

Das Aktienkapital des Unternehmens erhöht sich von aktuell CHF 289'199'160 um CHF 22'224'690 auf CHF 311'423'850. Die Kapitalerhöhung erfolgt durch Ausgabe von 740'823 Namensaktien mit einem Nennwert von jeweils CHF 30.00 (die "neuen Aktien") gegen Bareinlage aus dem bestehenden genehmigten Kapital gemäß Abschnitt 3a) der Satzung des Unternehmens (die "Kapitalerhöhung"). Die neuen Aktien haben volle Dividendenbezugsberechtigung für das Fiskaljahr 2020 mit Fiskaljahresbeginn 1. Januar 2020.

Die Kapitalerhöhung generiert Bruttoerlöse in Höhe von ca. CHF 212,6 Mio. Die beabsichtigte Mittelverwendung des Nettoerlöses umfasst (i) die Finanzierung der Markteinführung von eRx-Lösungen sowie europäischer Wachstumsinitiativen zur Verbreiterung der Kundenbasis durch organische Expansion sowie potenzielle Akquisitionen, (ii) Investitionen in Plattformen und Ökosystem-Partnerschaften, (iii) die Finanzierung der TeleClinic-Akquisition, sowie (iv) allgemeine Unternehmenszwecke.

Die neuen Aktien werden ohne Prospekt zum Handel im International Reporting Standard Segment der SIX Swiss Exchange zugelassen, unmittelbar nachdem die Kapitalerhöhung im Handelsregister eingetragen ist. Dies wird für den 20. Juli 2020 erwartet. Der erste Handelstag ist für den 21. Juli geplant.

Das Unternehmen ist an eine 90-tägige Lock-up-Periode ab Settlement Datum gebunden, vorbehaltlich üblicher Ausnahmen hiervon.

Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Switzerland

T +41 52 724 00 20
info@zurrose.com
zurrosegroup.com

Zur Rose Group

Jefferies und BofA Securities agierten als Joint Global Coordinators und Joint Bookrunners für die Kapitalerhöhung.

ACXIT Capital Partners agierte als Financial Advisor des Unternehmens.

Baker McKenzie agierte als Rechtsberaterin der Zur Rose-Gruppe.

Kontakt für Analysten und Investoren

Marcel Ziwica, Chief Financial Officer

E-Mail: ir@zurrose.com, Telefon: +41 58 810 11 49

Kontakt für Medien

Lisa Lüthi, Head of Group Communications

E-Mail: media@zurrose.com, Telefon: +41 52 724 08 14

Agenda

19. August 2020 Halbjahresergebnis

21. Oktober 2020 Q3 Trading Update

Zur Rose-Gruppe

Die Schweizer Zur Rose-Gruppe ist Europas grösste E-Commerce-Apotheke und eine der führenden Ärztégrossistinnen in der Schweiz. Darüber hinaus betreibt sie den in Südeuropa führenden Marktplatz für apothekenübliche Gesundheits- und Pflegeprodukte. Das Unternehmen ist international mit starken Marken präsent, unter anderem mit Deutschlands bekanntester Apothekenmarke DocMorris. Zur Rose beschäftigt an ihren Standorten in der Schweiz, Deutschland, den Niederlanden, Spanien und Frankreich über 1'800 Mitarbeitende. 2019 erwirtschaftete sie einen Umsatz von 1'569 Millionen Franken (inklusive medpex) bei rund 7 Millionen aktiven Kunden in Kernmärkten Europas.

Mit ihrem Geschäftsmodell bietet die Zur Rose-Gruppe eine qualitativ hochwertige, sichere und kostengünstige pharmazeutische Versorgung. Sie zeichnet sich zudem aus durch die stetige Weiterentwicklung digitaler Services im Bereich Arzneimittelmanagement unter Verwendung von KI-gestützten Anwendungen und neuen Technologien. Darüber hinaus treibt Zur Rose die Positionierung als umfassende Gesundheitsdienstleisterin aktiv voran. Mit dem Aufbau einer digitalen Gesundheitsplattform – das Zur Rose-Ökosystem – vernetzt sie Produkte, Dienstleistungen und digitale Services von qualifizierten Anbietern. Die Leistung von Zur Rose wird es sein, diese Angebote zu den Kunden und Patienten zu bringen und eine relevante Selektion vorzunehmen. Ziel ist es, die Menschen lückenlos zu begleiten und zu befähigen, die eigene Gesundheit mit Produkten und digitalen Lösungen optimal zu managen.

Die Aktien der Zur Rose Group AG sind an der SIX Swiss Exchange kotiert (Valor 4261528, ISIN CH0042615283, Ticker ROSE). Weitere Informationen unter zurrosegroup.com.

Disclaimer

THE CONTENTS OF THIS ANNOUNCEMENT HAVE BEEN PREPARED BY AND ARE THE SOLE RESPONSIBILITY OF ZUR ROSE GROUP AG (THE "COMPANY").

THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS FOR BACKGROUND PURPOSES ONLY AND DOES NOT PURPORT TO BE FULL OR COMPLETE. NO RELIANCE MAY BE PLACED BY ANY PERSON FOR ANY PURPOSE ON THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT OR ITS ACCURACY, FAIRNESS OR COMPLETENESS.

THIS INFORMATION DOES NOT CONSTITUTE AN OFFER OR INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES TO ANY PERSON IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR IN ANY JURISDICTION TO WHOM OR IN WHICH SUCH OFFER OR SOLICITATION IS UNLAWFUL. IT IS NOT BEING ISSUED IN COUNTRIES WHERE THE PUBLIC DISSEMINATION OF THE INFORMATION CONTAINED HEREIN MAY BE RESTRICTED OR PROHIBITED BY LAW. IN PARTICULAR, THIS INFORMATION IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA AND SHOULD NOT BE DISTRIBUTED TO PUBLICATIONS WITH A GENERAL CIRCULATION IN THE UNITED STATES. THE DISTRIBUTION OF THIS ANNOUNCEMENT MAY BE RESTRICTED BY LAW IN CERTAIN JURISDICTIONS AND PERSONS INTO WHOSE POSSESSION ANY DOCUMENT OR OTHER INFORMATION REFERRED TO HEREIN COMES SHOULD INFORM THEMSELVES ABOUT AND OBSERVE SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION. SECURITIES OF THE COMPANY ARE NOT BEING PUBLICLY OFFERED. IN PARTICULAR, THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE US SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES UNLESS THE SECURITIES ARE REGISTERED UNDER THE SECURITIES ACT, OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT IS AVAILABLE. THE ISSUER OF THE SECURITIES HAS NOT REGISTERED, AND DOES NOT INTEND TO REGISTER, ANY PORTION OF THE OFFERING OR SECURITIES IN THE UNITED STATES AND DOES NOT INTEND TO CONDUCT A PUBLIC OFFERING OF SECURITIES IN THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN AND WILL NOT BE REGISTERED UNDER THE APPLICABLE SECURITIES LAWS OF AUSTRALIA, CANADA OR JAPAN. SUBJECT TO CERTAIN EXCEPTIONS, THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED, SOLD OR DELIVERED WITHIN THE UNITED STATES EXCEPT IN AN "OFFSHORE TRANSACTION" IN ACCORDANCE WITH REGULATION S UNDER THE SECURITIES ACT OR FOR THE ACCOUNT OR BENEFIT OF ANY NATIONAL, RESIDENT OR CITIZEN OF AUSTRALIA, CANADA OR JAPAN. THIS ANNOUNCEMENT CONSTITUTES NEITHER AN OFFER TO SELL NOR A SOLICITATION TO BUY SECURITIES OF THE COMPANY AND IT DOES NOT CONSTITUTE A PROSPECTUS OR SIMILAR NOTICE WITHIN THE MEANING OF FORMER ARTICLES 652A, 752 AND/OR 1156 OF THE SWISS CODE OF OBLIGATIONS OR ARTICLES 35 ET SEQQ. AND 69 OF THE SWISS FINANCIAL SERVICES ACT OR A LISTING PROSPECTUS WITHIN THE MEANING OF THE LISTING RULES OF THE SIX SWISS EXCHANGE. THE SECURITIES ARE OFFERED AND LISTED WITHOUT THE PUBLICATION OF A PROSPECTUS IN RELIANCE ON THE EXEMPTIONS PROVIDED IN ARTICLE 36 PARAGRAPH 1 LETTER B AND ARTICLE 38 PARAGRAPH 1 LETTER A OF THE FINANCIAL SERVICES ACT.

IN EACH MEMBER STATE OF THE EUROPEAN ECONOMIC AREA AND THE UNITED KINGDOM (EACH, A "RELEVANT STATE"). THIS ANNOUNCEMENT AND ANY OFFER IF MADE SUBSEQUENTLY IS DIRECTED ONLY AT PERSONS WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF THE PROSPECTUS REGULATION (REGULATION (EU) 2017/1129) ("QUALIFIED INVESTORS"). THIS ANNOUNCEMENT IS BEING DISTRIBUTED ONLY TO, AND IS DIRECTED ONLY AT (I) PERSONS OUTSIDE THE UNITED KINGDOM, (II) PERSONS WHO HAVE PROFESSIONAL EXPERIENCE IN MATTERS RELATING TO INVESTMENTS FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005 (THE "ORDER") OR (III) HIGH NET WORTH ENTITIES, AND OTHER PERSONS TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED, FALLING WITHIN ARTICLE 49(2) OF THE ORDER (ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS "RELEVANT PERSONS"). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS COMMUNICATION RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED ONLY WITH RELEVANT PERSONS. ANY PERSON, WHO IS NOT A RELEVANT PERSON MUST NOT ACT OR RELY ON THIS COMMUNICATION OR ANY OF ITS CONTENTS.

THIS ANNOUNCEMENT MAY INCLUDE STATEMENTS THAT ARE, OR MAY BE DEEMED TO BE, "FORWARD-LOOKING STATEMENTS". THESE FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF FORWARD-LOOKING TERMINOLOGY, INCLUDING THE TERMS "BELIEVES", "ESTIMATES", "PLANS", "PROJECTS", "ANTICIPATES", "EXPECTS", "INTENDS", "MAY", "WILL" OR "SHOULD" OR, IN EACH CASE, THEIR NEGATIVE OR OTHER VARIATIONS OR COMPARABLE TERMINOLOGY, OR BY DISCUSSIONS OF STRATEGY, PLANS, OBJECTIVES, GOALS, FUTURE EVENTS OR INTENTIONS. FORWARD-LOOKING STATEMENTS MAY AND OFTEN DO DIFFER MATERIALLY FROM ACTUAL RESULTS. ANY FORWARD-LOOKING STATEMENTS REFLECT THE COMPANY'S CURRENT VIEW WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS RELATING TO FUTURE EVENTS AND OTHER RISKS, UNCERTAINTIES AND ASSUMPTIONS RELATING TO THE GROUP'S BUSINESS, RESULTS OF OPERATIONS, FINANCIAL POSITION, LIQUIDITY, PROSPECTS, GROWTH OR STRATEGIES. FORWARD-LOOKING STATEMENTS SPEAK ONLY AS OF THE DATE THEY ARE MADE.

EACH OF THE COMPANY, JEFFERIES AND MERRILL LYNCH INTERNATIONAL ("THE JOINT BOOKRUNNERS") AND THEIR RESPECTIVE AFFILIATES EXPRESSLY DISCLAIMS ANY OBLIGATION OR UNDERTAKING TO UPDATE, REVIEW OR REVISE ANY FORWARD LOOKING STATEMENT CONTAINED IN THIS ANNOUNCEMENT WHETHER AS A RESULT OF NEW INFORMATION, FUTURE DEVELOPMENTS OR OTHERWISE.

THE JOINT BOOKRUNNERS ARE ACTING EXCLUSIVELY FOR COMPANY AND NO-ONE ELSE IN CONNECTION WITH THE OFFERING. THEY WILL NOT REGARD ANY OTHER PERSON AS THEIR RESPECTIVE CLIENTS IN RELATION TO THE OFFERING AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN THE COMPANY FOR PROVIDING THE PROTECTIONS AFFORDED TO THEIR RESPECTIVE CLIENTS, NOR FOR PROVIDING ADVICE IN RELATION TO THE OFFERING, THE CONTENTS OF THIS ANNOUNCEMENT OR ANY TRANSACTION, ARRANGEMENT OR OTHER MATTER REFERRED TO HEREIN.

Not for release, publication or distribution in the United States, Canada, Australia or Japan.

IN CONNECTION WITH THE OFFERING, THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY TAKE UP A PORTION OF THE SECURITIES IN THE OFFERING AS A PRINCIPAL POSITION AND IN THAT CAPACITY MAY RETAIN, PURCHASE, SELL, OFFER TO SELL FOR THEIR OWN ACCOUNTS SUCH SECURITIES AND OTHER SECURITIES OF THE ISSUER OR RELATED INVESTMENTS IN CONNECTION WITH THE OFFERING OR OTHERWISE. ACCORDINGLY, REFERENCES TO THE SECURITIES BEING ISSUED, OFFERED, SUBSCRIBED, ACQUIRED, PLACED OR OTHERWISE DEALT IN SHOULD BE READ AS INCLUDING ANY ISSUE OR OFFER TO, OR SUBSCRIPTION, ACQUISITION, PLACING OR DEALING BY THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES ACTING IN SUCH CAPACITY. IN ADDITION THE JOINT BOOKRUNNERS, AND ANY OF THEIR AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS (INCLUDING SWAPS, WARRANTS OR CONTRACTS FOR DIFFERENCES) WITH INVESTORS IN CONNECTION WITH WHICH THE JOINT BOOKRUNNERS AND ANY OF THEIR AFFILIATES MAY FROM TIME TO TIME ACQUIRE, HOLD OR DISPOSE OF SECURITIES. THE JOINT BOOKRUNNERS DO NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR REGULATORY OBLIGATIONS TO DO SO.

NONE OF THE JOINT BOOKRUNNERS OR ANY OF THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES, ADVISERS OR AGENTS ACCEPTS ANY RESPONSIBILITY OR LIABILITY WHATSOEVER FOR OR MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO THE TRUTH, ACCURACY OR COMPLETENESS OF THE INFORMATION IN THIS ANNOUNCEMENT (OR WHETHER ANY INFORMATION HAS BEEN OMITTED FROM THE ANNOUNCEMENT) OR ANY OTHER INFORMATION RELATING TO THE COMPANY, ITS SUBSIDIARIES OR ASSOCIATED COMPANIES, WHETHER WRITTEN, ORAL OR IN A VISUAL OR ELECTRONIC FORM, AND HOWSOEVER TRANSMITTED OR MADE AVAILABLE OR FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS ANNOUNCEMENT OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION THEREWITH.